There are 1,990 papers on GLP-1 and incretin signaling in aging research: 292 trials and 282 observational studies in people, 178 in animals, 25 in cells, 1,113 reviews.
1,990 papers study it4 more mention it15 findings
228 new papers in 30 daysSee all 1,994 papers on GLP-1 and incretin signaling
At a glance
A human study reports no effect of GLP-1 and incretin signaling on estimated bone mineral density, while a mouse study shows activation by Citrus changshan huyou extract in the intestine. Reviews link the pathway to the incretin effect, reduced cardiovascular disease and lower body weight in humans; no independently replicated change is reported.
15 findings in 14 papers from 2016 to 2026, 6 of them since August 2026
The findings reach people, from one lab or study. 4 independent labs in 4 countries.
None of its findings points the other way.
- 4 independent labs in 4 countries
- Funders: Chinese Academy of Sciences and others
- Human trial292
- Humans282
- Animals177
- Model organisms1
- Cells25
- In silico23
Interventions
3Sleeve gastrectomy
upin humans1
1 study
Sleeve gastrectomy
upin humans1
Sleeve gastrectomy activates GLP-1 and incretin signaling in humans (severe obesity without diabetes).
“both groups exhibiting enhanced secretion of GLP-1 and GLP-2 following MTT”
Human trialsevere obesity without diabetes6 monthsn = 18
International journal of obesity (2005)
Tirzepatide
upin reviews1
1 study
Tirzepatide
upin reviews1
Tirzepatide activates GLP-1 and incretin signaling.
“Tirzepatide is a novel "twincretin" that functions as a dual glucose-dependent insulinotropic polypeptide and GLP-1 RA.”
Review
Tirzepatide for Weight Loss: Can Medical Therapy "Outweigh" Bariatric Surgery?
Cardiology in review
Caloric restriction
upin mice1
1 study
Caloric restriction
upin mice1
Caloric restriction activates GLP-1 and incretin signaling in db/db mice.
“GLP-1 pathway was reactivated with long-term CR.”
Animalsin db/db mice
Journal of diabetes research
Effects
6Glucose-dependent insulin secretion
upin reviews1
1 study
Glucose-dependent insulin secretion
upin reviews1
GLP-1 and incretin signaling increases glucose-dependent insulin secretion (diabetes mellitus).
“GLP-1 signaling and DPP-4 inhibition improve glucose-dependent insulin secretion while supporting β-cell survival and function.”
Reviewdiabetes mellituspancreatic beta cell
Current diabetes reviews
Cardiovascular disease
downin humans1
1 study
Cardiovascular disease
downin humans1
GLP-1 and incretin signaling decreases cardiovascular disease in humans.
“Obesity-related disease processes including type 2 diabetes mellitus, cardiovascular disease, chronic kidney disease, metabolic dysfunction-associated steatotic liver disease, and obstructive sleep apnea improve in patients treated with these medications”
Review
The Incretin Revolution: Integrating Incretin-Based Therapies into Clinical Care
Biomedical journal
Body weight
downin humans1
1 study
Body weight
downin humans1
GLP-1 and incretin signaling decreases body weight in humans.
“producing substantial weight loss and benefits across cardiometabolic outcomes.”
Review
Integrating incretin-based therapies into comprehensive obesity care: an EASO position statement
The Lancet regional health. Europe
Tumor growth
upin reviews1
1 study
Tumor growth
upin reviews1
GLP-1 and incretin signaling increases tumor growth in select receptor-expressing models.
“GLP-1 receptor activation may promote tumor growth in select receptor-expressing models”
Reviewin select receptor-expressing models
Cancer
Bone
upin humans1
1 study
Bone
upin humans1
GLP-1 and incretin signaling improves bone in patients with diabetes mellitus.
“therapies that are based on incretin effect, like Dipeptidyl peptidase-4 inhibitors (DPP-4i) and Glucagon-like peptide-1 receptor agonizts (GLP-1RAs) might have positive effects on bone health by promoting bone formation.”
Reviewin patients with diabetes mellitusbone
The effect of antidiabetic drugs on bone metabolism: a concise review
Endocrine
Insulin secretion
mediatesin humans1
1 study
Insulin secretion
mediatesin humans1
GLP-1 and incretin signaling mediates insulin secretion in humans after RYGBP.
“The improvement in insulin secretion rate and β-cell sensitivity to oral glucose after RYGBP is mediated by endogenous GLP-1”
Reviewafter RYGBP
Bariatric surgery and obesity: influence on the incretins
International journal of obesity supplements
Upstream
1Circadian misalignment
downin reviews1
1 study
Circadian misalignment
downin reviews1
circadian misalignment impairs GLP-1 and incretin signaling (from shift work, nocturnal light exposure, and sleep loss).
“the vulnerability of incretin rhythms to circadian misalignment from shift work, nocturnal light exposure, and sleep loss”
Reviewfrom shift work, nocturnal light exposure, and sleep loss
GLP-1 Receptor Agonists at the Crossroads of Circadian Biology, Sleep, and Metabolic Disease
International journal of molecular sciences
Associations
5Diet quality
mixedin humans1
1 study
Diet quality
mixedin humans1
Diet quality is associated with GLP-1 and incretin signaling in humans.
“Evidence consistently demonstrated that dietary quality influences endogenous GLP-1 signaling through nutrient-mediated secretion, gut microbiome-derived metabolites, inflammatory pathways, and metabolic regulation.”
Review
AHA Scientific Sessions 2026 abstract
Incretin effect
mixedin humans1
1 study
Incretin effect
mixedin humans1
GLP-1 and incretin signaling is associated with incretin effect in humans.
“elevated GLP-1 coexists with an impaired incretin effect because it is compensation for β-cell failure”
Review
Rise or fall? Reconciling contested directions in human gut hormone aging
Frontiers in endocrinology
Circadian clock
no changein reviews1
1 study
Circadian clock
no changein reviews1
GLP-1 and incretin signaling is associated with circadian clock.
“Emerging data suggest that GLP-1 signaling is under circadian regulation and may, in turn, influence central and peripheral clock systems.”
Review
GLP-1 Receptor Agonists at the Crossroads of Circadian Biology, Sleep, and Metabolic Disease
International journal of molecular sciences
Inflammation
mixedin reviews1
1 study
Inflammation
mixedin reviews1
GLP-1 and incretin signaling is associated with inflammation in Parkinson's disease models, convergence with proteostasis and mitochondrial homeostasis.
“We consolidate evidence across PI3K/Akt, MAPK/ERK, cAMP/PKA-CREB, and AMPK pathways, emphasising their convergence on mitochondrial homeostasis, proteostasis, neuroinflammation, and synaptic resilience.”
Reviewin Parkinson's disease models, convergence with proteostasis and mitochondrial homeostasis
GLP-1 Signalling as a Therapeutic Avenue in Parkinson's Disease: A Comprehensive Review
International journal of molecular sciences
Metformin
mixedin humans1
1 study
Metformin
mixedin humans1
Metformin is associated with GLP-1 and incretin signaling in the gut.
“In the gut, metformin modulates the glucagon-like peptide- 1 (GLP-1) - gut-brain axis and impacts the intestinal microbiota.”
Reviewin the gutgut
Repurposing Metformin for Vascular Disease
Current medicinal chemistry
Funding
171 grants since 2016National Institute of Diabetes and Digestive and Kidney Diseases$31.2MJapan Society for the Promotion of Science¥113MNational Heart, Lung, and Blood Institute$8.2M
Breast Cancer Research FoundationThe University of Texas MD Anderson Cancer Center225K2026–2027
National Institute of Diabetes and Digestive and Kidney DiseasesApplied Biotechnology Institute$288K2026–2028
National Institute of Diabetes and Digestive and Kidney DiseasesNew York University School of Medicine$36.9K2026–2028
Effects of GLP-1 Receptor Agonists on Airway Inflammation and Platelet Activation in Asthma
National Heart, Lung, and Blood InstituteBrigham and Women's Hospital$195K2022–2027
GLP-1 receptor agonists for the prevention and treatment of opioid use disorder
National Institute on Drug AbuseMayo Clinic Rochester$830K2026–2031
National Institute of Child Health and Human DevelopmentUniversity of Rochester$415K2026–2028
Advancing Sustainable Obesity Care: Integrating Food is Medicine with GLP-1 Receptor Agonists
National Heart, Lung, and Blood InstituteUniversity of Tx Md Anderson Can Ctr$104K2026–2031
National Institute for Health ResearchUniversity Hospitals Plymouth NHS Trust£2.8M2026–2030
The gut-brain axis and human higher cognition: GLP-1's role in controlling eating behaviour
Nederlandse Organisatie voor Wetenschappelijk OnderzoekRadboud University€1.5M2026
National Institute on Minority Health and Health DisparitiesUniversity of Florida$735K2026–2031
Contains public sector information licensed under the Open Government Licence v3.0.
How this record changed
Summary written from the findings.